Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe
Reacquiring rights to omaveloxolone from AbbVie looks great business
Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.
You may also be interested in...
Keeping Track Of Rolling Submissions: Gamida Cell, Roche, Lilly And Reata Are Latest To Use Fast Track
Applications are underway for omidubicel, mosenutuzumab, pirtobrutinib and omaveloxolone.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.